QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
NASDAQ:PYXS

Pyxis Oncology (PYXS) Stock Price, News & Analysis

$6.36
0.00 (0.00%)
(As of 02/29/2024 ET)
Today's Range
$6.11
$6.65
50-Day Range
$1.67
$6.37
52-Week Range
$1.35
$6.92
Volume
491,353 shs
Average Volume
851,594 shs
Market Capitalization
$281.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Pyxis Oncology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
41.5% Upside
$9.00 Price Target
Short Interest
Healthy
4.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of Pyxis Oncology in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.96) to ($1.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.14 out of 5 stars

Medical Sector

513th out of 958 stocks

Pharmaceutical Preparations Industry

245th out of 450 stocks


PYXS stock logo

About Pyxis Oncology Stock (NASDAQ:PYXS)

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

PYXS Stock Price History

PYXS Stock News Headlines

Pyxis Oncology Announces $50 Million Private Placement
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Pyxis Oncology Names Ken Kobayashi Chief Medical Officer
RBC Capital Reaffirms Their Buy Rating on Pyxis Oncology (PYXS)
LifeSci Capital Reaffirms Their Buy Rating on Pyxis Oncology (PYXS)
Pyxis Oncology Inc PYXS
Pyxis Oncology Inc.
See More Headlines
Receive PYXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2023
Today
2/29/2024
Next Earnings (Estimated)
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PYXS
Fax
N/A
Employees
67
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$14.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+41.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-120,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.58 per share

Miscellaneous

Free Float
40,600,000
Market Cap
$281.88 million
Optionable
Optionable
Beta
1.27
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. John L. Flavin M.B.A. (Age 53)
    MBA, Ph.D., Co-Founder & Independent Chairman
    Comp: $87.5k
  • Dr. Lara S. Sullivan M.D.
    MBA, CEO, President & Director
  • Ms. Pamela Yanchik Connealy M.B.A. (Age 62)
    CFO & COO
    Comp: $685.1k
  • Mr. Jitendra Wadhane (Age 43)
    Chief Accounting Officer, Senior VP of Finance & Corporate Controller
  • Dr. Balu N. Balasubramanian Ph.D.
    Interim Chief Technology Officer
  • Dr. Jan Pinkas Ph.D.
    Chief Scientific Officer
  • Dr. Charles T. Gombar Ph.D.
    Senior Vice President of Portfolio & Program Management
  • Mr. Ken Kobayashi FACP
    M.D., Chief Medical Officer














PYXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Pyxis Oncology stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pyxis Oncology in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PYXS shares.
View PYXS analyst ratings
or view top-rated stocks.

What is Pyxis Oncology's stock price target for 2024?

8 brokers have issued twelve-month price targets for Pyxis Oncology's stock. Their PYXS share price targets range from $4.00 to $14.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 41.5% from the stock's current price.
View analysts price targets for PYXS
or view top-rated stocks among Wall Street analysts.

How have PYXS shares performed in 2024?

Pyxis Oncology's stock was trading at $1.80 at the start of the year. Since then, PYXS shares have increased by 253.3% and is now trading at $6.36.
View the best growth stocks for 2024 here
.

Are investors shorting Pyxis Oncology?

Pyxis Oncology saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 1,280,000 shares, an increase of 63.1% from the January 31st total of 784,600 shares. Based on an average daily volume of 590,400 shares, the short-interest ratio is presently 2.2 days. Currently, 4.2% of the company's stock are sold short.
View Pyxis Oncology's Short Interest
.

When is Pyxis Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our PYXS earnings forecast
.

How were Pyxis Oncology's earnings last quarter?

Pyxis Oncology, Inc. (NASDAQ:PYXS) posted its earnings results on Friday, August, 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.24.

When did Pyxis Oncology IPO?

(PYXS) raised $158 million in an initial public offering on Friday, October 8th 2021. The company issued 10,500,000 shares at a price of $14.00-$16.00 per share.

Who are Pyxis Oncology's major shareholders?

Pyxis Oncology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.95%), abrdn plc (1.60%), Vestal Point Capital LP (0.99%), Decheng Capital LLC (0.74%), Dimensional Fund Advisors LP (0.23%) and Cable Car Capital LLC (0.14%). Insiders that own company stock include Darren S Cline, Jitendra Wadhane, Lara Sullivan, Mark Chin, Pamela Ann Connealy, Pfizer Inc and Thomas Civik.
View institutional ownership trends
.

How do I buy shares of Pyxis Oncology?

Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PYXS) was last updated on 2/29/2024 by MarketBeat.com Staff